trimethyloxamine has been researched along with Disbacteriosis in 44 studies
trimethyloxamine: used in manufacture of quaternary ammonium cpds; insect attractant; warming agent for gas; oxidant; structure
trimethylamine N-oxide : A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Gut dysbiosis increases with aging, and it has been associated with the impairment of gut barrier function leading to the leakage of harmful metabolites such as trimethylamine (TMA)." | 9.41 | The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease. ( Al-Arawe, N; El Hage, R; Hinterseher, I, 2023) |
| "Iron-overload leads to gut dysbiosis/inflammation and disturbance of metabolites, and deferiprone alleviates those conditions more effectively in WT than in those that are thalassemic." | 8.12 | Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study. ( Buddhasiri, S; Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kittichotirat, W; Kumfu, S; Nawara, W; Sarichai, P; Sriwichaiin, S; Thiennimitr, P; Thonusin, C, 2022) |
| "Trimethylamine-N-oxide (TMAO), a derivative from the gut microbiota metabolite trimethylamine (TMA), has been identified to be an independent risk factor for promoting atherosclerosis." | 8.02 | Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome. ( Du, Y; Hong, B; Jiang, J; Jiang, Z; Li, X; Su, C; Wang, L; Yang, M; Yang, Y; Zhang, J; Zhang, X; Zhang, Y, 2021) |
| " Gut dysbiosis increases with aging, and it has been associated with the impairment of gut barrier function leading to the leakage of harmful metabolites such as trimethylamine (TMA)." | 5.41 | The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease. ( Al-Arawe, N; El Hage, R; Hinterseher, I, 2023) |
| "Iron-overload leads to gut dysbiosis/inflammation and disturbance of metabolites, and deferiprone alleviates those conditions more effectively in WT than in those that are thalassemic." | 4.12 | Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study. ( Buddhasiri, S; Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kittichotirat, W; Kumfu, S; Nawara, W; Sarichai, P; Sriwichaiin, S; Thiennimitr, P; Thonusin, C, 2022) |
| "Trimethylamine-N-oxide (TMAO), a derivative from the gut microbiota metabolite trimethylamine (TMA), has been identified to be an independent risk factor for promoting atherosclerosis." | 4.02 | Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome. ( Du, Y; Hong, B; Jiang, J; Jiang, Z; Li, X; Su, C; Wang, L; Yang, M; Yang, Y; Zhang, J; Zhang, X; Zhang, Y, 2021) |
| "Trimethylamine-N-oxide (TMAO), a gut-microbiota-dependent metabolite generated from its dietary precursors such as choline, has been identified as an independent risk factor for atherosclerosis." | 4.02 | Metformin alleviates choline diet-induced TMAO elevation in C57BL/6J mice by influencing gut-microbiota composition and functionality. ( Du, Y; Hong, B; Li, X; Su, C; Wang, L; Yang, Y; Zhang, X, 2021) |
| "Choline is a water-soluble nutrient essential for human life." | 2.66 | The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases. ( Allison, J; Arboleya, S; Arias, JL; Arias, N; Gueimonde, M; Higarza, SG; Kaliszewska, A, 2020) |
| "Inflammation is the key for the initiation and progression of atherosclerosis." | 2.66 | Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis. ( Chen, YH; Kao, HL; Liu, SF; Wu, MS; Wu, WK; Yang, KC; Yeh, CF, 2020) |
| "Dysbiosis is associated with intestinal inflammation and reduced integrity of the gut barrier, which in turn increases circulating levels of bacterial structural components and microbial metabolites that may facilitate the development of CVD." | 2.58 | The gut microbiota as a novel regulator of cardiovascular function and disease. ( Battson, ML; Gentile, CL; Lee, DM; Weir, TL, 2018) |
| "Gut dysbiosis was associated with increased levels of TMAO, immature OCN-expressing EPCs, and CAD." | 1.62 | Compositional change of gut microbiome and osteocalcin expressing endothelial progenitor cells in patients with coronary artery disease. ( Ahmad, A; Corban, MT; Horwath, IE; Lerman, A; Lerman, LO; Loeffler, DL; Marietta, EV; Murray, JA; Ozcan, I; Sara, JD; Toya, T, 2021) |
| "Obesity is considered an important factor that increases the risk of colorectal cancer (CRC)." | 1.56 | Gut Microbiota-Mediated Inflammation and Gut Permeability in Patients with Obesity and Colorectal Cancer. ( Gómez-Millán, J; Laborda-Illanes, A; Medina, JA; Ordóñez, R; Otero, A; Plaza-Andrade, I; Queipo-Ortuño, MI; Ramos-Molina, B; Sánchez-Alcoholado, L, 2020) |
| "This dysbiosis was correlated with the severity of the disease." | 1.42 | Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack. ( Chen, Q; He, Y; Liao, SX; Liu, FT; Pan, SY; Wang, S; Xia, GH; Yin, J; You, C; Zhou, HW; Zhou, L; Zhu, JJ, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (38.64) | 24.3611 |
| 2020's | 27 (61.36) | 2.80 |
| Authors | Studies |
|---|---|
| Annunziata, G | 1 |
| Ciampaglia, R | 1 |
| Capò, X | 1 |
| Guerra, F | 1 |
| Sureda, A | 1 |
| Tenore, GC | 1 |
| Novellino, E | 1 |
| Bin-Jumah, MN | 1 |
| Gilani, SJ | 1 |
| Hosawi, S | 1 |
| Al-Abbasi, FA | 2 |
| Zeyadi, M | 1 |
| Imam, SS | 1 |
| Alshehri, S | 1 |
| Ghoneim, MM | 1 |
| Nadeem, MS | 1 |
| Kazmi, I | 1 |
| Lanz, M | 1 |
| Janeiro, MH | 1 |
| Milagro, FI | 1 |
| Puerta, E | 1 |
| Ludwig, IA | 1 |
| Pineda-Lucena, A | 1 |
| Ramírez, MJ | 1 |
| Solas, M | 1 |
| Sriwichaiin, S | 1 |
| Thiennimitr, P | 1 |
| Thonusin, C | 1 |
| Sarichai, P | 1 |
| Buddhasiri, S | 1 |
| Kumfu, S | 1 |
| Nawara, W | 1 |
| Kittichotirat, W | 1 |
| Fucharoen, S | 1 |
| Chattipakorn, N | 1 |
| Chattipakorn, SC | 1 |
| Schoch, L | 3 |
| Sutelman, P | 3 |
| Suades, R | 3 |
| Badimon, L | 3 |
| Moreno-Indias, I | 3 |
| Vilahur, G | 3 |
| El Hage, R | 1 |
| Al-Arawe, N | 1 |
| Hinterseher, I | 1 |
| Hemmati, M | 1 |
| Kashanipoor, S | 1 |
| Mazaheri, P | 1 |
| Alibabaei, F | 1 |
| Babaeizad, A | 1 |
| Asli, S | 1 |
| Mohammadi, S | 1 |
| Gorgin, AH | 1 |
| Ghods, K | 1 |
| Yousefi, B | 1 |
| Eslami, M | 1 |
| Craven, H | 1 |
| Erlandsson, H | 1 |
| McGuinness, D | 1 |
| McGuinness, DH | 1 |
| Mafra, D | 1 |
| Ijaz, UZ | 1 |
| Bergman, P | 2 |
| Shiels, PG | 1 |
| Stenvinkel, P | 2 |
| Papa, A | 1 |
| Santini, P | 1 |
| De Lucia, SS | 1 |
| Maresca, R | 1 |
| Porfidia, A | 1 |
| Pignatelli, P | 1 |
| Gasbarrini, A | 1 |
| Violi, F | 1 |
| Pola, R | 1 |
| Chan, MM | 1 |
| Yang, X | 1 |
| Wang, H | 2 |
| Saaoud, F | 1 |
| Sun, Y | 1 |
| Fong, D | 1 |
| Hardin, SJ | 1 |
| Singh, M | 1 |
| Eyob, W | 1 |
| Molnar, JC | 1 |
| Homme, RP | 1 |
| George, AK | 1 |
| Tyagi, SC | 1 |
| Wang, J | 1 |
| Gu, X | 1 |
| Yang, J | 2 |
| Wei, Y | 1 |
| Zhao, Y | 1 |
| Moludi, J | 1 |
| Maleki, V | 1 |
| Jafari-Vayghyan, H | 1 |
| Vaghef-Mehrabany, E | 1 |
| Alizadeh, M | 1 |
| Koay, YC | 1 |
| Chen, YC | 1 |
| Wali, JA | 1 |
| Luk, AWS | 1 |
| Li, M | 1 |
| Doma, H | 1 |
| Reimark, R | 1 |
| Zaldivia, MTK | 1 |
| Habtom, HT | 1 |
| Franks, AE | 1 |
| Fusco-Allison, G | 1 |
| Holmes, A | 1 |
| Simpson, SJ | 1 |
| Peter, K | 1 |
| O'Sullivan, JF | 1 |
| Zhang, B | 1 |
| Wang, X | 1 |
| Xia, R | 1 |
| Li, C | 1 |
| Arias, N | 1 |
| Arboleya, S | 1 |
| Allison, J | 1 |
| Kaliszewska, A | 1 |
| Higarza, SG | 1 |
| Gueimonde, M | 1 |
| Arias, JL | 1 |
| Sánchez-Alcoholado, L | 1 |
| Ordóñez, R | 1 |
| Otero, A | 1 |
| Plaza-Andrade, I | 1 |
| Laborda-Illanes, A | 1 |
| Medina, JA | 1 |
| Ramos-Molina, B | 1 |
| Gómez-Millán, J | 1 |
| Queipo-Ortuño, MI | 1 |
| Yeh, CF | 1 |
| Chen, YH | 1 |
| Liu, SF | 1 |
| Kao, HL | 2 |
| Wu, MS | 3 |
| Yang, KC | 1 |
| Wu, WK | 3 |
| Naqvi, S | 1 |
| Asar, TO | 1 |
| Kumar, V | 1 |
| Alhayyani, S | 1 |
| Kamal, MA | 1 |
| Anwar, F | 1 |
| Zhao, J | 1 |
| Ning, X | 1 |
| Liu, B | 1 |
| Dong, R | 1 |
| Bai, M | 1 |
| Sun, S | 1 |
| Baragetti, A | 1 |
| Severgnini, M | 1 |
| Olmastroni, E | 1 |
| Dioguardi, CC | 1 |
| Mattavelli, E | 1 |
| Angius, A | 1 |
| Rotta, L | 1 |
| Cibella, J | 1 |
| Caredda, G | 1 |
| Consolandi, C | 1 |
| Grigore, L | 1 |
| Pellegatta, F | 1 |
| Giavarini, F | 1 |
| Caruso, D | 1 |
| Norata, GD | 1 |
| Catapano, AL | 1 |
| Peano, C | 1 |
| Du, D | 1 |
| Tang, W | 1 |
| Zhou, C | 1 |
| Sun, X | 1 |
| Wei, Z | 1 |
| Zhong, J | 1 |
| Huang, Z | 1 |
| Zhao, X | 1 |
| Chen, Y | 1 |
| Li, L | 2 |
| Zhai, J | 1 |
| Yu, B | 1 |
| Yang, D | 1 |
| Wang, Q | 1 |
| Chang, Y | 1 |
| Li, J | 2 |
| Zhang, P | 1 |
| Zhang, H | 1 |
| Li, Y | 1 |
| Toya, T | 1 |
| Ozcan, I | 1 |
| Corban, MT | 1 |
| Sara, JD | 1 |
| Marietta, EV | 1 |
| Ahmad, A | 1 |
| Horwath, IE | 1 |
| Loeffler, DL | 1 |
| Murray, JA | 1 |
| Lerman, LO | 1 |
| Lerman, A | 1 |
| Li, X | 3 |
| Su, C | 2 |
| Jiang, Z | 1 |
| Yang, Y | 2 |
| Zhang, Y | 1 |
| Yang, M | 1 |
| Zhang, X | 2 |
| Du, Y | 2 |
| Zhang, J | 2 |
| Wang, L | 2 |
| Jiang, J | 1 |
| Hong, B | 2 |
| Taguchi, K | 1 |
| Fukami, K | 1 |
| Elias, BC | 1 |
| Brooks, CR | 1 |
| Yuzefpolskaya, M | 1 |
| Bohn, B | 1 |
| Javaid, A | 1 |
| Mondellini, GM | 1 |
| Braghieri, L | 1 |
| Pinsino, A | 1 |
| Onat, D | 1 |
| Cagliostro, B | 1 |
| Kim, A | 1 |
| Takeda, K | 1 |
| Naka, Y | 1 |
| Farr, M | 1 |
| Sayer, GT | 1 |
| Uriel, N | 1 |
| Nandakumar, R | 1 |
| Mohan, S | 1 |
| Colombo, PC | 1 |
| Demmer, RT | 1 |
| Xu, KY | 1 |
| Xia, GH | 2 |
| Lu, JQ | 1 |
| Chen, MX | 1 |
| Zhen, X | 1 |
| Wang, S | 2 |
| You, C | 2 |
| Nie, J | 1 |
| Zhou, HW | 2 |
| Yin, J | 3 |
| Cui, X | 1 |
| Ye, L | 1 |
| Jin, L | 1 |
| Wang, W | 1 |
| Li, S | 1 |
| Bao, M | 1 |
| Wu, S | 1 |
| Geng, B | 1 |
| Zhou, X | 2 |
| Cai, J | 1 |
| Leng, J | 1 |
| Proudman, C | 1 |
| Darby, A | 1 |
| Blow, F | 1 |
| Townsend, N | 1 |
| Miller, A | 1 |
| Swann, J | 1 |
| Battson, ML | 1 |
| Lee, DM | 1 |
| Weir, TL | 1 |
| Gentile, CL | 1 |
| Li, DY | 1 |
| Tang, WHW | 1 |
| Missailidis, C | 1 |
| Neogi, U | 1 |
| Trøseid, M | 1 |
| Nowak, P | 1 |
| Bielinska, K | 1 |
| Radkowski, M | 1 |
| Grochowska, M | 1 |
| Perlejewski, K | 1 |
| Huc, T | 1 |
| Jaworska, K | 1 |
| Motooka, D | 1 |
| Nakamura, S | 1 |
| Ufnal, M | 1 |
| Chen, CC | 1 |
| Liu, PY | 1 |
| Panyod, S | 1 |
| Liao, BY | 1 |
| Chen, PC | 1 |
| Kuo, HC | 1 |
| Kuo, CH | 1 |
| Chiu, THT | 1 |
| Chen, RA | 1 |
| Chuang, HL | 1 |
| Huang, YT | 1 |
| Zou, HB | 1 |
| Hsu, CC | 1 |
| Chang, TY | 1 |
| Lin, CL | 1 |
| Ho, CT | 1 |
| Yu, HT | 1 |
| Sheen, LY | 2 |
| Gong, J | 1 |
| Noel, S | 1 |
| Pluznick, JL | 1 |
| Hamad, ARA | 1 |
| Rabb, H | 1 |
| Arduini, A | 1 |
| Zammit, VA | 1 |
| Bonomini, M | 1 |
| Jin, M | 1 |
| Qian, Z | 1 |
| Xu, W | 1 |
| Srinivasa, S | 1 |
| Fitch, KV | 1 |
| Lo, J | 1 |
| Kadar, H | 1 |
| Knight, R | 2 |
| Wong, K | 1 |
| Abbara, S | 1 |
| Gauguier, D | 1 |
| Capeau, J | 1 |
| Boccara, F | 1 |
| Grinspoon, SK | 1 |
| Liao, SX | 1 |
| He, Y | 1 |
| Liu, FT | 1 |
| Zhu, JJ | 1 |
| Chen, Q | 1 |
| Zhou, L | 1 |
| Pan, SY | 1 |
| Milani, C | 1 |
| Ferrario, C | 1 |
| Turroni, F | 1 |
| Duranti, S | 1 |
| Mangifesta, M | 1 |
| van Sinderen, D | 1 |
| Ventura, M | 1 |
| Bergeron, N | 1 |
| Williams, PT | 1 |
| Lamendella, R | 1 |
| Faghihnia, N | 1 |
| Grube, A | 1 |
| Wang, Z | 1 |
| Jansson, JK | 1 |
| Hazen, SL | 1 |
| Krauss, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Washed Microbiota Transplantation (WMT) for Chronic Kidney Disease (CKD): a Open Label, Multicenter Trial[NCT05838118] | 100 participants (Anticipated) | Interventional | 2023-04-20 | Recruiting | |||
| Investigation on the Effect of Carnitine Supplement on Gut Microbiota and TMAO Production Capacity[NCT02838732] | 56 participants (Actual) | Interventional | 2016-05-18 | Completed | |||
| Association Analysis of Cardiovascular and Nervous System Diseases and Intestinal Microbiome Based on Multi-omics Big Data and Related Applications[NCT06099496] | 490 participants (Anticipated) | Observational [Patient Registry] | 2023-04-01 | Recruiting | |||
| A Randomised, Double-blinded, Cross-over, Placebo- Controlled Pilot Study to Investigate the Effect of Tomato Extract on TMAO in Overweight or Obese Adults[NCT04160481] | 37 participants (Actual) | Interventional | 2019-11-12 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for trimethyloxamine and Disbacteriosis
| Article | Year |
|---|---|
Polycystic ovary syndrome and cardiovascular risk. Could trimethylamine N-oxide (TMAO) be a major player? A potential upgrade forward in the DOGMA theory.
Topics: Animals; Bacteria; Cardiovascular Diseases; Dysbiosis; Female; Gastrointestinal Microbiome; Heart Di | 2021 |
Pathobiological Relationship of Excessive Dietary Intake of Choline/L-Carnitine: A TMAO Precursor-Associated Aggravation in Heart Failure in Sarcopenic Patients.
Topics: Biodiversity; Biomarkers; Carnitine; Choline; Dietary Supplements; Disease Susceptibility; Dysbiosis | 2021 |
The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease.
Topics: Aged; Aging; Animals; Atherosclerosis; Dysbiosis; Gastrointestinal Microbiome; Humans; Methylamines | 2023 |
Importance of gut microbiota metabolites in the development of cardiovascular diseases (CVD).
Topics: Atherosclerosis; Cardiovascular Diseases; Dysbiosis; Gastrointestinal Microbiome; Humans; Inflammati | 2023 |
Gut dysbiosis-related thrombosis in inflammatory bowel disease: Potential disease mechanisms and emerging therapeutic strategies.
Topics: Dysbiosis; Endotoxemia; Gastrointestinal Diseases; Humans; Inflammatory Bowel Diseases; Lipopolysacc | 2023 |
The Microbial Metabolite Trimethylamine N-Oxide Links Vascular Dysfunctions and the Autoimmune Disease Rheumatoid Arthritis.
Topics: Amyloid; Animals; Arthritis, Rheumatoid; Autoimmune Diseases; Cardiovascular Diseases; Diet; Dysbios | 2019 |
Diet-induced chronic syndrome, metabolically transformed trimethylamine-N-oxide, and the cardiovascular functions.
Topics: Animals; Atherosclerosis; Bacteria; Diet, High-Fat; Dysbiosis; Endothelium, Vascular; Gastrointestin | 2019 |
Metabolic endotoxemia and cardiovascular disease: A systematic review about potential roles of prebiotics and probiotics.
Topics: Animals; Bacteria; Cardiovascular Diseases; Dysbiosis; Endotoxemia; Gastrointestinal Microbiome; Hea | 2020 |
Gut microbiota in coronary artery disease: a friend or foe?
Topics: Animals; Bacteria; Coronary Artery Disease; Coronary Vessels; Dysbiosis; Gastrointestinal Microbiome | 2020 |
The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases.
Topics: Animals; Biological Availability; Cardiovascular Diseases; Choline; Diet; Dysbiosis; Gastrointestina | 2020 |
Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis.
Topics: Animals; Atherosclerosis; Clinical Trials as Topic; Cytokines; Disease Progression; Dysbiosis; Fatty | 2020 |
A cross-talk between gut microbiome, salt and hypertension.
Topics: Animals; Bacteria; Blood Pressure; Diet, Healthy; Diet, Sodium-Restricted; Dietary Fiber; Dietary Su | 2021 |
Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review.
Topics: Bacteria; Dysbiosis; Gastrointestinal Microbiome; Humans; Methylamines; Renal Insufficiency, Chronic | 2021 |
Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease.
Topics: Animals; Cardiovascular Diseases; Disease Progression; Dysbiosis; Gastrointestinal Microbiome; Glyca | 2021 |
The gut microbiota as a novel regulator of cardiovascular function and disease.
Topics: Aging; Animals; Anti-Bacterial Agents; Atherosclerosis; Bile Acids and Salts; Cardiovascular Disease | 2018 |
Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease.
Topics: Animals; Cardiovascular Diseases; Cresols; Diet Therapy; Dietary Supplements; Dysbiosis; Enzyme Inhi | 2018 |
Gut Microbiota-Kidney Cross-Talk in Acute Kidney Injury.
Topics: Acute Kidney Injury; Animals; Blood Pressure; Dysbiosis; Fatty Acids, Volatile; Gastrointestinal Mic | 2019 |
The role of intestinal microbiota in cardiovascular disease.
Topics: Bile Acids and Salts; Cardiovascular Diseases; Dysbiosis; Fatty Acids; Gastrointestinal Microbiome; | 2019 |
3 trials available for trimethyloxamine and Disbacteriosis
| Article | Year |
|---|---|
The gut microbiome dysbiosis is recovered by restoring a normal diet in hypercholesterolemic pigs.
Topics: Animals; Cholesterol; Diet; Diet, High-Fat; Dysbiosis; Gastrointestinal Microbiome; Noncommunicable | 2023 |
The gut microbiome dysbiosis is recovered by restoring a normal diet in hypercholesterolemic pigs.
Topics: Animals; Cholesterol; Diet; Diet, High-Fat; Dysbiosis; Gastrointestinal Microbiome; Noncommunicable | 2023 |
The gut microbiome dysbiosis is recovered by restoring a normal diet in hypercholesterolemic pigs.
Topics: Animals; Cholesterol; Diet; Diet, High-Fat; Dysbiosis; Gastrointestinal Microbiome; Noncommunicable | 2023 |
The gut microbiome dysbiosis is recovered by restoring a normal diet in hypercholesterolemic pigs.
Topics: Animals; Cholesterol; Diet; Diet, High-Fat; Dysbiosis; Gastrointestinal Microbiome; Noncommunicable | 2023 |
Effect of DLT-SML on Chronic Stable Angina Through Ameliorating Inflammation, Correcting Dyslipidemia, and Regulating Gut Microbiota.
Topics: Adult; Aged; Angina, Stable; Anti-Inflammatory Agents; Bacteria; Biomarkers; China; Cytokines; Drug | 2021 |
Diets high in resistant starch increase plasma levels of trimethylamine-N-oxide, a gut microbiome metabolite associated with CVD risk.
Topics: Adult; Biomarkers; Body Mass Index; California; Cardiovascular Diseases; Cross-Over Studies; Diet, C | 2016 |
23 other studies available for trimethyloxamine and Disbacteriosis
| Article | Year |
|---|---|
Trimethylamine N-oxide (TMAO) drives insulin resistance and cognitive deficiencies in a senescence accelerated mouse model.
Topics: Animals; Cognition; Dementia; Disease Models, Animal; Dysbiosis; Gastrointestinal Microbiome; Insuli | 2022 |
Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study.
Topics: Animals; Cytokines; Deferiprone; Diet; Dysbiosis; Gastrointestinal Microbiome; Inflammation; Iron; I | 2022 |
A normative microbiome is not restored following kidney transplantation.
Topics: Dysbiosis; Gastrointestinal Microbiome; Humans; Kidney Transplantation; Microbiota; Renal Insufficie | 2023 |
Gut Microbiota Dysbiosis and Increased Plasma LPS and TMAO Levels in Patients With Preeclampsia.
Topics: Adult; Biomarkers; Case-Control Studies; Dysbiosis; Feces; Female; Gastrointestinal Microbiome; Huma | 2019 |
Plasma levels of trimethylamine-N-oxide can be increased with 'healthy' and 'unhealthy' diets and do not correlate with the extent of atherosclerosis but with plaque instability.
Topics: Animal Feed; Animals; Atherosclerosis; Bacteria; Biomarkers; Carotid Artery Diseases; Choline; Coron | 2021 |
Gut Microbiota-Mediated Inflammation and Gut Permeability in Patients with Obesity and Colorectal Cancer.
Topics: Aged; Bacteria; Biomarkers; Body Mass Index; Colorectal Neoplasms; Dysbiosis; Feces; Female; Gastroi | 2020 |
Gut Microbiota Functional Dysbiosis Relates to Individual Diet in Subclinical Carotid Atherosclerosis.
Topics: Adult; Aged; Aged, 80 and over; Bacteria; Carnitine; Carotid Artery Diseases; Choline; Diet; Dysbios | 2021 |
Fecal Microbiota Transplantation Is a Promising Method to Restore Gut Microbiota Dysbiosis and Relieve Neurological Deficits after Traumatic Brain Injury.
Topics: Animals; Brain; Brain Injuries, Traumatic; Dysbiosis; Fecal Microbiota Transplantation; Gastrointest | 2021 |
Compositional change of gut microbiome and osteocalcin expressing endothelial progenitor cells in patients with coronary artery disease.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD34; Case-Control Studies; Cells, Cultured; Clostridiales; Co | 2021 |
Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome.
Topics: Animals; Atherosclerosis; Berberine; Choline; Diet; Disease Models, Animal; Disease Susceptibility; | 2021 |
Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis.
Topics: Aged; Aged, 80 and over; Dysbiosis; Female; Gastrointestinal Microbiome; Heart Failure; Heart Transp | 2021 |
Metformin alleviates choline diet-induced TMAO elevation in C57BL/6J mice by influencing gut-microbiota composition and functionality.
Topics: Akkermansia; Animals; Atherosclerosis; Bifidobacterium; Choline; Diabetes Mellitus, Type 2; Diet; Dy | 2021 |
Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients.
Topics: Adult; Aged; Animals; Betaine; Carnitine; Case-Control Studies; Choline; Clostridiaceae; Dysbiosis; | 2017 |
Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients.
Topics: Adult; Aged; Bacteria; Butyrates; Dysbiosis; Female; Gastrointestinal Microbiome; Heart Failure; Hum | 2018 |
Exploration of the Fecal Microbiota and Biomarker Discovery in Equine Grass Sickness.
Topics: Acetylcarnitine; Animals; Bacteroidetes; Biomarkers; Clostridium botulinum; Cresols; Dysbiosis; Fece | 2018 |
The microbial metabolite trimethylamine-N-oxide in association with inflammation and microbial dysregulation in three HIV cohorts at various disease stages.
Topics: Adult; Aged; Bacterial Translocation; Cardiovascular Diseases; Cluster Analysis; DNA, Bacterial; DNA | 2018 |
High salt intake increases plasma trimethylamine N-oxide (TMAO) concentration and produces gut dysbiosis in rats.
Topics: Animals; Dysbiosis; Feces; Gastrointestinal Microbiome; Intestinal Diseases; Male; Methylamines; Rat | 2018 |
Identification of TMAO-producer phenotype and host-diet-gut dysbiosis by carnitine challenge test in human and germ-free mice.
Topics: Animals; Cardiovascular Diseases; Carnitine; Diet; Dysbiosis; Feeding Behavior; Gastrointestinal Mic | 2019 |
Identification of trimethylamine N-oxide (TMAO)-producer phenotype is interesting, but is it helpful?
Topics: Animals; Carnitine; Diet; Dysbiosis; Humans; Methylamines; Mice; Phenotype | 2020 |
Response to the letter: Identification of trimethylamine N-oxide (TMAO)-producer phenotype is interesting, but is it helpful?
Topics: Animals; Carnitine; Diet; Dysbiosis; Humans; Methylamines; Mice; Phenotype | 2020 |
Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine.
Topics: Choline; Coronary Artery Disease; Dysbiosis; Female; HIV Infections; Humans; Intestinal Diseases; Ma | 2015 |
Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Bacteria; Carotid Artery Diseases; Case-Control Stud | 2015 |
The human gut microbiota and its interactive connections to diet.
Topics: Animals; Autoimmune Diseases; Bile Acids and Salts; Diet, Healthy; Diet, Western; Dysbiosis; Fatty A | 2016 |